CClinicalTrials.gg
Status unknownNCT04346485Updated Jul 22, 2021

Comparison of SP TFL and Ho:YAG for RIRS Using 145 µm and 200 µm Fibers

An interventional study of SP TFL RIRS with 145 mcm fiber and SP TFL RIRS with 200 mcm fiber in Kidney Stone, Nephrolithiasis and Urolithiasis, sponsored by I.M. Sechenov First Moscow State Medical University. Status unknown at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-22.

Sponsored by I.M. Sechenov First Moscow State Medical University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2021), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The authors hypothesize that the RIRS using 150-microm Tm-fiber laser is superior than fiber with larger diameters, as 200-microm Tm-fiber laser or 200-microm holmium fiber laser, in such points as follows:

  • decreasing surgery time and laser-on time due to possibility of 4.3 fold ablation efficacy increase, which has been shown by Andreeva et al.;
  • increasing the flexible ureteroscope tip deflection lower pole stones availability;
  • decreased risk of complications and a better irrigation and visualization due to better irrigation with smaller fiber;
  • increasing of lithotripsy efficacy and laser beam density by lowering of beam focal spot due to using of lesser fiber diameter
Read the detailed description

RIRS will be performed with SP TFL or Ho:YAG (100 W). The procedure is performed under general anesthesia with the patient in the dorsal lithotomy position. The bladder is entered either with a cystoscope or a semi-rigid ureterorenoscope. Guidewires (0.035") will be used to facilitate access (under fluoroscopic guidance). After access sheath (12/14) will be placed up to the kidney pelvis. Through the access sheath ureteroscope will be introduced. For nephrolithotripsy 145 mcm and 200 mcm fibers will be used. Large fragments could be extracted with nitinol basket. After the surgery ureteral stent (7 Fr.) will be placed inside the ureter for 10 to 14 days.

A 10 Fr urethral catheter can be placed in the bladder for the drainage of the bladder during the operation.

02

Conditions studied

  • Kidney Stone
  • Nephrolithiasis
  • Urolithiasis

Keywords

  • RIRS
  • holmium laser
  • superpulse thulium laser
  • kidney stone disease
03

In context

Kidney Calculi

598 studies on the registry are indexed under Kidney Calculi; 163 are open to participants now.

This study's planned enrollment of 105 is above the median of 90 across 461 interventional studies indexed under Kidney Calculi.

Browse Kidney Calculi studies →

Lead sponsor

I.M. Sechenov First Moscow State Medical University is the lead sponsor of 133 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Males and Females > 18 y.o.;
  • Radiologically confirmed (CT) kidney stone;
  • Stone size from 10 to 20 mm.

Exclusion criteria

Exclusion Criteria:

  • Multiple (more than 3) kidney stones > 5 mm
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    SP TFL RIRS with 145 mcm fiber

    Superpulse thulium fiber laser RIRS with 145 mcm laser fiber

    Procedure: SP TFL RIRS with 145 mcm fiber

  • Experimental
    SP TFL RIRS with 200 mcm fiber

    Superpulse thulium fiber laser RIRS with 200 mcm laser fiber

    Procedure: SP TFL RIRS with 200 mcm fiber

  • Active comparator
    Ho:YAG RIRS with 200 mcm fiber

    Ho:YAG laser RIRS with 200 mcm laser fiber

    Procedure: Ho:YAG RIRS with 200 mcm fiber

Interventions

  • ProcedureSP TFL RIRS with 145 mcm fiber

    retrograde intrarenal surgery

  • ProcedureSP TFL RIRS with 200 mcm fiber

    retrograde intrarenal surgery

  • ProcedureHo:YAG RIRS with 200 mcm fiber

    retrograde intrarenal surgery

06

What researchers measure

Primary outcomes

  1. Laser-on time

    Time of laser emission during surgery, seconds

    Time frame: during surgery

Secondary outcomes

  1. adverse events

    Complications according to Clavien-Dindo classification (higher score means more severe complication)

    Time frame: during surgery and 6 months after surgery

  2. Operative time

    Surgery duration, minutes

    Time frame: during surgery

  3. Hemoglobin drop

    Change of hemoglobin level 1 day after surgery comparing to pre-operative value, g/L

    Time frame: 1 day after surgery

  4. Catheter stay

    duration of catheterisation, days

    Time frame: 1 week

  5. hospitalization length

    Duration of hospital stay after surgery, days

    Time frame: 1 week

  6. Radiation exposure

    Duration of X-ray exposure, sec.

    Time frame: during surgery

  7. Radiation exposure

    Effective dose, mSv

    Time frame: during surgery

  8. Stone-free rate

    Percentage of patients with absence of stones larger 3 mm in maximum size on follow-up CT

    Time frame: 3 month

07

Study locations

1 of 1 sites recruiting
  • Institute for Urology and Reproductive Health, Sechenov University.
    Moscow, 119991, Russian Federation
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04346485
Lead sponsor
I.M. Sechenov First Moscow State Medical University
Responsible party
Dmitry Enikeev, MD, PhD (Deputy director for research, I.M. Sechenov First Moscow State Medical University) — Principal investigator
First posted
Apr 15, 2020
Start date
Mar 13, 2020
Primary completion
May 31, 2022 (estimated)
Completion
May 31, 2022 (estimated)
Last update
Jul 22, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion